Company Shares of Quintiles Transitional Holdings (NYSE:Q) Rally 6.81%

Quintiles Transitional Holdings (NYSE:Q) : Traders are bullish on Quintiles Transitional Holdings (NYSE:Q) as it has outperformed the S&P 500 by a wide margin of 7.18% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 5.45%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 6.81% in the last 1 week, and is up 8.91% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

The company shares have dropped -5.09% from its 1 Year high price. On Jul 29, 2015, the shares registered one year high at $80.45 and the one year low was seen on Feb 9, 2016. The 50-Day Moving Average price is $65.97 and the 200 Day Moving Average price is recorded at $65.53.

The stock has recorded a 20-day Moving Average of 9.88% and the 50-Day Moving Average is 7.99%.


Quintiles Transitional Holdings (NYSE:Q): stock turned positive on Friday. Though the stock opened at $69.22, the bulls momentum made the stock top out at $71.425 level for the day. The stock recorded a low of $68.91 and closed the trading day at $71.41, in the green by 3.51%. The total traded volume for the day was 1,997,216. The stock had closed at $68.99 in the previous days trading.

In an insider trading activity,The officer (EVP and COO) of Quintiles Transnational Holdings Inc., Gordon Kevin K sold 24,000 shares at $66.41 on June 9, 2016. The Insider selling transaction had a total value worth of $1,593,840. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.

Quintiles Transnational Holdings Inc. is a biopharmaceutical services company. The Company is a provider of biopharmaceutical development services and commercial outsourcing services. The Company is engaged in the development and commercialization of pharmaceutical therapies. It also offers therapeutic, scientific and analytical services to its biopharmaceutical and other healthcare customers. The Company offers its services through two segments: Product Development and Integrated Healthcare Services. Its product development segment is a contract research organization (CRO) and is focused on Phase II-IV clinical trials and associated laboratory and analytical activities. Its Integrated Healthcare Services segment provides services, including commercial services, such as contract pharmaceutical sales forces, and healthcare business services, such as phase research, market access and consulting, and health information analytics and technology consulting.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.